# BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

> **NCT00346255** · PHASE1 · COMPLETED · sponsor: **ImmunoGen, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** BB-10901

## Key facts

- **NCT ID:** NCT00346255
- **Lead sponsor:** ImmunoGen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2013-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00346255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00346255, "BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00346255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*